Biotech entity
Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. That works out to roughly 0.8 stories per week across a 17-day span. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Mar 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. That works out to roughly 0.8 stories per week across a 17-day span. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. They are better corroborated than the beat average, carrying 4 original sources each against 3.4 for the same window. Coverage clusters in ipo, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention Insulet, published between February 18, 2026 and March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 190 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Insulet. Shared-story counts are live from our verified record — not editorial picks.
IPO Pricing
MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
Analyst Debate
Market analysts debate the valuation of the diabetes unit amid competitive pressures.
Initial Filing
Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.
Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Source: finanznachrichten.de · rttnews.com
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
Insulet is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
